International Journal of Drug Delivery Technology
Volume 15, Issue 1

Design, Development and Evaluation of Liposomal Formulations of Fulvestrant for Targeted Drug Delivery Breast Cancer

Dinesh Shinde, Ganesh Basarkar, Chandrashekhar Upasani

SNJBs Sureshdada Jain College of Pharmacy, Chandwad, Nashik, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India. 

Received: 18th Dec, 2024; Revised: 19th Jan, 2025; Accepted: 11th Feb, 2025; Available Online: 25th Mar, 2025 

ABSTRACT

Mainaim of current research was to determine feasibility of developing, designing, and testing liposomal formulations loaded with Fulvestrant for purpose of targeted drug transfer in management of breast cancer. With an impressive encapsulation effectiveness of 85%, they were made utilizing the thin-film hydration approach solvent evaporation followed high pressure homogenization technique for particle size reduction..The physicochemical characterization, these liposomess were seen to be in the dimension of <150-200nm with low polydispersity index (<0.3), -25 mV of the zeta potential, and indicated stability and will also be best for an in vivo application. Ex-vivo diffusion will reveal high numbers of drugs being released as compared to free Fulvestrant and further made the release sustained over 48 hours. Cytotoxic evaluation of MCF-7 breast cancer cells was exhibited that for fulvestrant-loaded liposomes at 5 μM, there was a 50% reduction of cell viability-which is an extremely significant increase compared with free drug (30% reduction). Pharmacokinetic study did exhibit an improvement in bioavailability due to increased circulation time, fetching changes in drug accumulation into tumor tissues through enhancement of permeability and retention phenomenon. It means nearly all formulations have comparatively mild hemolytic activity less than 5%, thereby exhibiting probable safety. This study brings into light a very feasible total approach of Fulvestrant-loaded liposomes for a prolonged tumor targeting by showing diminished exposures to such drug as compared to conventional injectable therapies offering therapeutic potential enhancement with lesser side effects. The overall findings would provide good ground to conduct further in vivo testing of these formulations for clinical applicability.

Keywords: Fulvestrant, liposomes, breast cancer, drug delivery, encapsulation efficiency, sustained release, cytotoxicity, pharmacokinetics, ex-vivo diffusion, targeted therapy.

How to cite this article: Dinesh Shinde, Ganesh Basarkar, Chandrashekhar Upasani. Design, Development and Evaluation of Liposomal Formulations of Fulvestrant for Targeted Drug Delivery Breast Cancer. International Journal of Drug Delivery Technology, 2025;15(1):66-75. doi: 10.25258/ijddt.15.1.9

REFERENCES

  1. Sunilkumar MM, Finni CG, Lijimol AS, Rajagopal MR. Health-related suffering and palliative care in breast cancer. Current Breast Cancer Reports. 2021 Dec;13:241-6.https://doi.org/10.1007/s12609-021-00431-1
  2. Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics. 2021 May 14;13(5):723.https://doi.org/10.3390/pharmaceutics13050723
  3. Downton T, Zhou F, Segara D, Jeselsohn R, Lim E. Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status. Drug Design, Development and Therapy. 2022 Jan 1:2933-48.https://doi.org/10.2147/DDDT.S380925
  4. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, Goodacre S. GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. Journal of Medicinal Chemistry. 2021 Jul 12;64(16):11841-56.https://doi.org/10.1021/acs.jmedchem.1c00847
  5. Antimisiaris SG, Marazioti A, Kannavou M, Natsaridis E, Gkartziou F, Kogkos G, Mourtas SJ. Overcoming barriers by local drug delivery with liposomes. Advanced drug delivery reviews. 2021 Jul 1;174:53-86.https://doi.org/10.1016/j.addr.2021.01.019
  6. De Leo V, Maurelli AM, Giotta L, Catucci L. Liposomes containing nanoparticles: preparation and applications. Colloids and Surfaces B: Biointerfaces. 2022 Oct 1;218:112737.https://doi.org/10.1016/j.colsurfb.2022.112737
  7. Dymek M, Sikora E. Liposomes as biocompatible and smart delivery systems–the current state. Advances in colloid and interface science. 2022 Nov 1;309:102757.https://doi.org/10.1016/j.cis.2022.102757
  8. Onzi G, Guterres SS, Pohlmann AR, Frank LA. Passive targeting and the enhanced permeability and retention (EPR) effect. the ADME encyclopedia: a comprehensive guide on biopharmacy and pharmacokinetics. 2021:1-3. https://doi.org/10.1007/978-3-030-51519-5_108-1
  9. Nsairat H, Al-Sulaibi M, Alshaer W. PEGylatednanoassemblies composed of edelfosine and fulvestrant drugs: In vitro antiproliferative effect against breast cancer cells. Journal of Drug Delivery Science and Technology. 2023 Aug 1;85:104612.https://doi.org/10.1016/j.jddst.2023.104612
  10. Gupta K, Shrivastava P. Development and validation of UV spectrophotometric method for trimethoprim in pure and marketed formulation. International Journal of Health Sciences. 2022;6.https://doi.org/10.53730/ijhs.v6nS2.7860
  11. Nekkalapudi AR, Veldi VG, Pippalla S. A novel RP-HPLC method for estimating fulvestrant, benzoyl alcohol, and benzyl benzoate in injection formulation. American Journal of Analytical Chemistry. 2022 Jul 7;13(7):229-40.https://doi.org/10.4236/ajac.2022.137016
  12. Rajana N, Chary PS, Bhavana V, Deshmukh R, Dukka K, Sharma A, Mehra NK. Targeted delivery and apoptosis induction of CDK-4/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells. International Journal of Pharmaceutics. 2024 Feb 15;651:123787.https://doi.org/10.1016/j.ijpharm.2024.123787
  13. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon. 2022 May 1;8(5).https://doi.org/10.1016/j.heliyon.2022.e09394
  14. Pande S. Factors affecting response variables with emphasis on drug release and loading for optimization of liposomes. Artificial Cells, Nanomedicine, and Biotechnology. 2024 Dec 31;52(1):334-44.https://doi.org/10.1080/21691401.2024.2360634
  15. Sedky NK, Braoudaki M, Mahdy NK, Amin K, Fawzy IM, Efthimiadou EK, Youness RA, Fahmy SA. Box–Behnken design of thermo-responsive nano-liposomes loaded with a platinum (IV) anticancer complex: evaluation of cytotoxicity and apoptotic pathways in triple negative breast cancer cells. Nanoscale Advances. 2023;5(19):5399-413.https://doi.org/10.1039/D3NA00368J
  16. Lima Salviano T, dos Santos M, Charles D, de SiqueiraFerrazCarvalho R, Pereira MA, de Arruda B, Santos V, dos Santos Aguiar J, Souto FO, da Silva C, da Paz M. Fucoidan-coated liposomes: a target system to deliver the antimicrobial drug usnic acid to macrophages infected with Mycobacterium tuberculosis. Journal of biomedical nanotechnology. 2021 Aug 1;17(8):1699-710.https://doi.org/10.1166/jbn.2021.3139
  17. Ravar F, Saadat E, Gholami M, Dehghankelishadi P, Mahdavi M, Azami S, Dorkoosh FA. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. Journal of controlled release. 2016 May 10;229:10-22.https://doi.org/10.1016/j.jconrel.2016.03.012
  18. Xu Y, Yao Y, Wang L, Chen H, Tan N. Hyaluronic acid coated liposomes Co-delivery of natural cyclic peptide RA-XII and mitochondrial targeted photosensitizer for highly selective precise combined treatment of colon cancer. International Journal of Nanomedicine. 2021 Jul 22:4929-42.https://doi.org/10.2147/IJN.S311577
  19. Rahman M, Singh JG, Afzal O, Altamimi AS,
  20. Alrobaian M, Haneef J, Barkat MA, Almalki WH, Handa M, Shukla R, Nasar Mir NajibUllah S. Preparation, Characterization, and Evaluation of Curcumin–Graphene Oxide Complex-Loaded Liposomes against Staphylococcus aureus in Topical Disease. ACS omega. 2022 Nov 20;7(48):43499-509.https://doi.org/10.1021/acsomega.2c03940
  21. Rahman M, Singh JG, Afzal O, Altamimi AS, Alrobaian M, Haneef J, Barkat MA, Almalki WH, Handa M, Shukla R, Nasar Mir NajibUllah S. Preparation, Characterization, and Evaluation of Curcumin–Graphene Oxide Complex-Loaded Liposomes against Staphylococcus aureus in Topical Disease. ACS omega. 2022 Nov 20;7(48):43499-509.https://doi.org/10.1016/j.actbio.2021.12.019
  22. Wei TT, Cao BB, Hao XL, Gu JY, Wu RG. The interaction of baicalein with dipalmitoylphosphatidylcholine liposomes: differential scanning calorimetry, synchrotron X-ray diffraction, and fourier transform infrared studies. ThermochimicaActa. 2021 Sep 1;703:178993.https://doi.org/10.1016/j.tca.2021.178993
  23. Nsairat H, Alshaer W, Lafi Z, Ahmad S, Al-Sanabrah A, El-Tanani M. Development and validation of reversed-phase-HPLC method for simultaneous quantification of fulvestrant and disulfiram in liposomes. Bioanalysis. 2023 Dec 1;15(23):1393https://doi.org/10.4155/bio-2023-0137
  24. Porbaha P, Ansari R, Kiafar MR, Bashiry R, Khazaei MM, Dadbakhsh A, Azadi A. A Comparative Mathematical Analysis of Drug Release from Lipid-Based Nanoparticles. AAPS PharmSciTech. 2024 Sep 5;25(7):208.https://doi.org/10.1208/s12249-024-02922-7
  25. Jyothi VG, Bulusu R, Rao BV, Pranothi M, Banda S, Bolla PK, Kommineni N. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update. International Journal of Pharmaceutics. 2022 Aug 25;624:122022.https://doi.org/10.1016/j.ijpharm.2022.122022
  26. Pund S, Chandak R, Rajurkar V, Kharat N, Khalil SS, Shaikh S, Parve K, Kadam M, Choudante S, Pulate C, Wakale V. A review on nanomedicines in treatment of thyroid and their applications in management of thyroid disorders. International journal of health sciences. 2022;6(S5):11141-54.
  27. Gao Y, Gu W, Chen L, Xu Z, Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 2008 Oct 1;29(30):4129-36.https://doi.org/10.1016/j.biomaterials.2008.07.008
  28. Mane V, Killedar S, More H, Tare H. Preclinical study on camellia sinensis extract-loaded nanophytosomes for enhancement of memory-boosting activity: optimization by central composite design. Future Journal of Pharmaceutical Sciences. 2024 May 1;10(1):66.
  29. Mane V, Killedar S, More H, Nadaf S, Salunkhe S, Tare H. Novel Phytosomal Formulation of Emblica officinalis Extracts with Its In Vivo Nootropic Potential in Rats: Optimization and Development by Box‐Behnken Design. Journal of Chemistry. 2024;2024(1):6644815.
  30. Sonawane A, Jawale G, Devhadrao N, Bansode A, Lokhande J, Kherade D, Sathe P, Deshmukh N, Dama G, Tare H. Formulation and Development of Mucoadhesive Nasal Drug Delivery of Ropinirol HCl for Brain Targeting. International Journal of Applied Pharmaceutics. 2023;15(5):325-32.